Ms. Murphy began consulting for Aduro on the LADD program in 2009. She joined the company as director of clinical operations in 2011 and was promoted to senior director of clinical development and operations in 2013. Prior to Aduro, Ms. Murphy advanced the development of the LADD platform at both Cerus Corp. and Anza Therapeutics, where she managed the first Phase I studies to support what are now Aduro's LADD clinical programs.
“Aimee’s promotion speaks to her invaluable contributions to Aduro and our clinical programs,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “Her achievements, which include overseeing our Phase II trials in pancreatic cancer and the development of CRS-207 in mesothelioma, play a key role in the advancement of our clinical programs. She has been an instrumental member of our team and we look forward to her continued leadership.”